Source-grounded facts extracted from Hyperfine, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hyperfine, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.
“The appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: Votes For Votes Against Votes Abstained Broker Non-Votes 341,824,976 3,658,781 209,580 —”
Hyperfine, Inc. shareholders approved Election of Directors at the 2026-05-21 meeting.
“The following nominees were reelected to serve on the Company's Board of Directors until the Company’s 2027 annual meeting of stockholders and until their respective successors have been elected and qualified, based on the following votes: Name Votes For Votes Against Votes Abstained Broker Non-Votes Daniel J. Wolterman 314,507,148 1,119,985 74,738 29,991,466 Maria Sainz 314,632,923 996,652 72,296 29,991,466 John Dahldorf 314,717,927 909,207 74,737 29,991,466 Ruth Fattori 314,704,628 925,051 72,192 29,991,466 Jonathan M. Rothberg, Ph.D. 315,051,080 574,206 76,585 29,991,466”
Hyperfine, Inc. reported the first quarter ended March 31, 2026 results: revenue $3.90 million, net income $8.62 million, EPS $0.09 per share. Guidance reaffirmed.
“extending the expected cash runway into 2028, and providing capital for commercial growth. First Quarter 2026 Financial Results • Revenues for the first quarter of 2026 were $3.90 million, increasing 83% compared to $2.14 million in the first quarter of 2025. • Sold 10 commercial Swoop® systems in the first quarter of 2026, compared to six in the first quarter of”
Hyperfine, Inc. reported full year 2026 results: revenue approximately $20 to $22 million. Guidance initiated.
“Management expects revenue for the full year 2026 to be approximately $20 to $22 million”
Hyperfine, Inc. reported full year ended December 31, 2025 results: revenue $13.56 million, net income $35.57 million, EPS $0.43 per share. Guidance reaffirmed.
“of 2025 net loss includes a gain from the change in fair value of warrant liabilities of $1.46 million. Full Year 2025 Financial Results • Revenues for the full year 2025 were $13.56 million, increasing 5.2% compared to $12.89 million in 2024. • Sold net 38 commercial Swoop® systems in 2025, compared to 48 in 2024. • Gross profit for the full year 2025 was $6.75”
Hyperfine, Inc. reported fourth quarter ended December 31, 2025 results: revenue $5.29 million, net income $5.91 million, EPS $0.06 per share.
“equity financing and the initial debt tranche, providing capital for commercial growth. Fourth Quarter 2025 Financial Results • Revenues for the fourth quarter of 2025 were $5.29 million, increasing 128% compared to $2.32 million in the fourth quarter of 2024. • Sold net 16 commercial Swoop® systems in the fourth quarter of 2025, compared to nine in the fourth”
Hyperfine, Inc. issued 520,835 shares of warrant to Horizon Technology Finance Corporation for $1.20 per share.
“the Company issued to the Lender (i) warrants to purchase up to an aggregate of 562,500 shares (the “Initial Warrants”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants to purchase up to an aggregate of 520,835 shares (the “Additional Warrants”) of Common Stock, in each case at an exercise price of $1.20 per share (collectively, the “Warrants”).”
Hyperfine, Inc. issued 562,500 shares of warrant to Horizon Technology Finance Corporation for $1.20 per share.
“the Company issued to the Lender (i) warrants to purchase up to an aggregate of 562,500 shares (the “Initial Warrants”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants to purchase up to an aggregate of 520,835 shares (the “Additional Warrants”) of Common Stock, in each case at an exercise price of $1.20 per share (collectively, the “Warrants”).”
Hyperfine, Inc. incurred term loan of up to $40.0 million with Horizon Technology Finance Corporation at prime rate plus 4.25% with the prime rate having a floor of 6.50%; provided that maturing March 18, 2031.
“corporation, as lender and collateral agent (the “Lender”). The Loan Agreement provides for a senior secured term loan facility in an aggregate principal amount of up to $40.0 million (collectively, the “Term Loans”). The proceeds of the Term Loans will be used for working capital and general corporate purposes. The Company borrowed $15.0 million of Term Loans”
Hyperfine, Inc. entered into Loan and Security Agreement with Horizon Technology Finance Corporation valued at up to $40.0 million (effective 2026-03-18).
“On March 18, 2026 (the “Closing Date”), Hyperfine, Inc. (the “Company” or the “Borrower”) entered into a Loan and Security Agreement (the “Loan Agreement”) by and between the Company, as borrower, and Horizon Technology Finance Corporation, a Delaware corporation, as lender and collateral agent (the “Lender”).”
Hyperfine, Inc. amended Amended and Restated At Market Issuance Sales Agreement with B. Riley Securities, Inc. and BTIG, LLC valued at up to $50.0 million (effective 2025-12-29).
“On December 29, 2025, Hyperfine, Inc. (the “Company”) entered into an Amended and Restated At Market Issuance Sales Agreement (the “Amended and Restated Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) and BTIG, LLC (“BTIG”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), having an aggregate offering price of up to $50.0 million”
Daniel J. Wolterman was appointed as Chairperson at Hyperfine, Inc..
“the Board appointed Daniel J. Wolterman, a current member of the Board, as Chairperson of the Board.”
R. Scott Huennekens resigned as Chairperson at Hyperfine, Inc..
“R. Scott Huennekens, Chairperson of the Board of Directors (the “Board”) of Hyperfine, Inc. (the “Company”), notified the Company of his decision to resign as Chairperson and member of the Board, effective as of May 22, 2025”
Hyperfine, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
“April 30, 2025, Hyperfine, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Notice”
Hyperfine, Inc. announced a restructuring with charges of up to $0.4 million (approximately 14% of its global workforce).
“sufficient to iterate the Swoop® system technology further and execute on its strategy. In connection with the restructuring, the Company currently estimates it will incur up to $0.4 million of costs, consisting primarily of cash severance costs, other severance benefits and other related restructuring costs. The Company expects to substantially complete the”
Hyperfine, Inc. reported first quarter ended March 31, 2024 results: revenue $3.30 million, net income $9.85 million, EPS $0.14 per share. Guidance reaffirmed.
“Stroke Conference and 17 at International Society for Magnetic Resonance Medicine. First Quarter 2024 Financial Results • Revenues for the first quarter of 2024 were $3.30 million, up 25%, compared to $2.64 million in the first quarter of 2023. • Hyperfine, Inc. sold 13 commercial Swoop® systems in the first quarter of 2024. • Gross margin for the first”
Hyperfine, Inc. reported the fiscal year ended December 31, 2023 results: revenue $11.03 million, net income Net loss for the full year 2023 was $44.24 million, equating to a net loss of $0.62 per share. Guidance initiated.
“• Revenues for the full year 2023 were $11.03 million, up 62%, compared to $6.81 million in 2022.”
Hyperfine, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $2.69 million, net income net loss of $10.68 million, equating to a net loss of $0.15 per share.
“• Revenues for the fourth quarter of 2023 were $2.69 million, up 89%, compared to $1.42 million in the fourth quarter of 2022.”
Hyperfine, Inc. entered into Sales Agreement with B. Riley Securities, Inc. valued at $50.0 million (effective 2023-11-09).
“On November 9, 2023, Hyperfine, Inc. (the “Company”) entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), having an aggregate offering price of up to $50.0 million (the “Placement Shares”) through or to B. Riley as sales agent or principal.”
Hyperfine, Inc. reported the full year 2023 results: revenue $11 to $13 million. Guidance initiated.
“Management expects revenue for the full year 2023 to be $11 to $13 million.”
Hyperfine, Inc. reported the nine months ended September 30, 2023 results: revenue $8.35 million, net income $33.55 million, EPS $0.47 per share.
“Revenues for the nine months ended September 30, 2023 were $8.35 million, compared to $5.39 million in the nine months ended September 30, 2022.”
Hyperfine, Inc. reported the third quarter ended September 30, 2023 results: revenue $2.33 million, net income $10.76 million, EPS $0.15 per share.
“progress on all our clinical programs, including our upcoming Alzheimer’s feasibility study.” Third Quarter 2023 Financial Results • Revenues for the third quarter of 2023 were $2.33 million, compared to $2.35 million in the third quarter of 2022. • Hyperfine, Inc. sold six commercial Swoop® systems in the third quarter of 2023. • Gross margin for the third quarter”
Khan Siddiqui was terminated as Chief Medical Officer and Chief Strategy Officer at Hyperfine, Inc..
“On September 27, 2023, Hyperfine, Inc. (the “Company”) terminated Khan Siddiqui, M.D.’s part-time employment as the Company’s Chief Medical Officer and Chief Strategy Officer, effective September 30, 2023”
Hyperfine, Inc. reported six months ended June 30, 2023 results: revenue $6.02 million, net income $22.80 million, EPS $0.32 per share.
“net loss of $23.16 million, or a net loss of $0.33 per share, for the second quarter of 2022. Six Months Financial Results • Revenues for the six months ended June 30, 2023 were $6.02 million, compared to $3.04 million in the six months ended June 30, 2022. • Gross margin for the six months ended June 30, 2023 was $2.60 million, compared to $(0.08) million in the six”
Hyperfine, Inc. reported second quarter ended June 30, 2023 results: revenue $3.38 million, net income $10.64 million, EPS $0.15 per share.
“brain imaging for clinicians and their patients across multiple care settings globally.” Second Quarter 2023 Financial Results • Revenues for the second quarter of 2023 were $3.38 million, compared to $1.53 million in the second quarter of 2022. • Hyperfine, Inc. sold 14 commercial Swoop® systems in the second quarter of 2023. • Gross margin for the second quarter”
Khan Siddiqui changed role as Chief Medical Officer and Chief Strategy Officer at Hyperfine, Inc..
“the Company entered into a schedule and salary modification letter agreement (the “Modification Agreement”) with Khan Siddiqui, M.D., the Company’s Chief Medical Officer and Chief Strategy Officer, effective July 24, 2023.”
Thomas Teisseyre was appointed as Chief Operating Officer at Hyperfine, Inc..
“Thomas Teisseyre, Ph.D., the Company’s Chief Product Officer, has been appointed by the Board of Directors of the Company (the “Board”) to serve as Chief Operating Officer of the Company, effective as of July 24, 2023”
Hyperfine, Inc.: Filed Certificate of Amendment to limit officer liability under recent Delaware law (effective 2023-06-09).
“On June 9, 2023, the Company filed a Certificate of Amendment to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to limit the liability of its officers as permitted by recent amendments to Delaware law (the “Charter Amendment”).”
Hyperfine, Inc.: Amended and restated bylaws to provide for a Chairperson in lieu of an Executive Chairman (effective 2023-06-08).
“On June 8, 2023, the Board of Directors (the “Board”) of Hyperfine, Inc. (the “Company”) approved an amendment and restatement of the Company’s Bylaws (the “Amended and Restated Bylaws”), effective as of June 8, 2023, to provide for the Company to have a Chairperson in lieu of an Executive Chairman.”
Hyperfine, Inc. shareholders approved Charter Amendment to limit liability of officers as permitted by recent amendments to Delaware law at the 2023-06-08 meeting.
“The Charter Amendment was approved, based on the following votes:”
Hyperfine, Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“The appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified, based on the following votes:”
Hyperfine, Inc. shareholders approved Election of directors at the 2023-06-08 meeting.
“The following nominees were reelected to serve on the Board until the Company’s 2024 annual meeting of stockholders and until their respective successors have been elected and qualified, based on the following votes:”
Hyperfine, Inc. reported first quarter ended March 31, 2023 results: revenue $2.64 million, net income $12.16 million, EPS $0.17 per share. Guidance initiated.
“to deliver on the vision to expand access to MRI for clinicians and their patients globally.” First Quarter 2023 Financial Results • Revenues for the first quarter of 2023 were $2.64 million, compared to $1.51 million in the first quarter of 2022. • Hyperfine, Inc. installed 10 commercial Swoop systems in the first quarter of 2023. • Gross margin for the first”
Hyperfine, Inc. dismissed Deloitte & Touche LLP as its auditor.
“On March 24, 2023, the Audit Committee also dismissed Deloitte & Touche LLP ("Deloitte") as the Company’s independent registered public accounting firm.”
Hyperfine, Inc. engaged Grant Thornton LLP as its auditor.
“appointed Grant Thornton LLP ("Grant Thornton") as the Company’s independent registered public accounting firm”
Hyperfine, Inc. reported the full year 2023 results: revenue $10 to $14 million. Guidance initiated.
“2023 Financial Guidance • Management expects revenue for the full year 2023 to be $10 to $14 million. • Management expects cash burn for the full year to be $40 to $45 million.”
Hyperfine, Inc. reported the full year 2022 results: revenue $6.814 million, net income $73.164 million, EPS $1.04 per share.
“Full Year 2022 Financial Results • Revenues for the full year 2022 were $6.814 million, compared to $1.496 million in 2021. • Gross margin for the full year 2022 was $0.907 million, compared to $(1.167) million in 2021. • Research and development expenses for the full year 2022 were $28.156 million, compared to $25.842 million in 2021. • Sales, general, and administrative expenses for full year 2022 were $46.625 million, compared to $37.859 million in 2021. • Net loss for the full year was $73.164 million, equating to a net loss of $1.04 per share, as compared to a net loss of $64.851 million, or a net loss of $17.57 per share, for the prior year.”
Hyperfine, Inc. reported the fourth quarter of 2022 results: revenue $1.424 million, net income $13.059 million, EPS $0.19 per share.
“Fourth Quarter 2022 Financial Results • Revenues for the fourth quarter of 2022 were $1.424 million, compared to $0.436 million in the fourth quarter of 2021. • Gross margin for the fourth quarter of 2022 was $0.300 million, compared to $(0.453) million in the fourth quarter of 2021. • Research and development expenses for the fourth quarter of 2022 were $5.219 million, compared to $8.893 million in the fourth quarter of 2021. • Sales, general, and administrative expenses for the fourth quarter of 2022 were $8.710 million, compared to $16.741 million in the fourth quarter of 2021. • Net loss for the fourth quarter was $13.059 million, equating to a net loss of $0.19 per share, as compared to a net loss of $26.085 million, or a net loss of $2.73 per share, for the same period of the prior year.”
Hyperfine, Inc. reported the full year 2023 results: revenue $10 to $14 million. Guidance initiated.
“Management expects revenue for the full year 2023 to be $10 to $14 million.”
Hyperfine, Inc. reported the full year 2022 results: revenue $6.814 million, net income $73.164 million, EPS $1.04 per share.
“today announced fourth quarter and full year 2022 financial results and provided a business update. “We made measurable progress at Hyperfine over the past year. We delivered $6.8 million in revenue in 2022, received multiple FDA clearances and international approvals, including CE Marking, in recent months, and saw a large number of publications and presentations”
Hyperfine, Inc. reported the fourth quarter of 2022 results: revenue $1.424 million, net income $13.059 million, EPS $0.19 per share.
“right-sized organization to extend Hyperfine, Inc.’s cash runway through the end of 2025. Fourth Quarter 2022 Financial Results • Revenues for the fourth quarter of 2022 were $1.424 million, compared to $0.436 million in the fourth quarter of 2021. • Gross margin for the fourth quarter of 2022 was $0.300 million, compared to $(0.453) million in the fourth quarter of”
Alok Gupta was terminated as Chief Financial Officer at Hyperfine, Inc..
“On February 3, 2023, the Company determined that the employment of Alok Gupta, the Company’s current Chief Financial Officer, will terminate effective as of March 31, 2023.”
Brett Hale was appointed as Chief Financial Officer and Chief Administrative Officer at Hyperfine, Inc..
“On February 8, 2023, Hyperfine, Inc. (the “Company”) announced that Brett Hale has been appointed by the Board of Directors of the Company (the “Board”) to serve as Chief Administrative Officer of the Company, effective as of February 13, 2023”
Hyperfine, Inc. announced a restructuring with charges of up to $1.7 million affecting global workforce, including subsidiary Liminal Sciences, Inc. (approximately 13% of its global workforce).
“On December 6, 2022, Hyperfine, Inc. (the “Company”) committed to an organizational restructuring designed to decrease its costs and create a more streamlined organization to support its business. As a result, the Company has terminated approximately 13% of its global workforce including, among others, the employees of its subsidiary, Liminal Sciences, Inc. In connection with the restructuring, the Company currently estimates it will incur up to $1.7 million of costs, consisting primarily of cash severance costs, other severance benefits, fixed asset impairment costs and other related restructuring costs.”
Hyperfine, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“December 6, 2022, Hyperfine, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). This Noti”
Neela Paykel was terminated as General Counsel, Chief Compliance Officer, and Corporate Secretary at Hyperfine, Inc..
“terminated the employment of Neela Paykel as General Counsel, Chief Compliance Officer, and Corporate Secretary of the Company, effective December 9, 2022.”
Hyperfine, Inc. received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1), 5615(c)).
“November 7, 2022. However, the Company’s notice to Nasdaq was in error. As previously disclosed, the Company is relying on the controlled company exemption in Nasdaq Listing Rule 5615(c), which exempts controlled companies (defined as a company of which more than 50% of the voting power for the election of directors is held by an individual, a group, or another company) from the requirements of certain corporate governance rules, including Nasdaq’s Majority Independent Board requirement. Nasdaq has been informed that the Company is a “controlled company” and has withdrawn its notice. Despite t”
Hyperfine, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(a)(2), 5605(b)(1), 5605(b)(1)(A)).
“October 24, 2022, Hyperfine, Inc. (the “Company”) believes that Maria Sainz, a current director of the Company and a member of the audit committee of the board of directors of the Company (the “Board”), may no longer be considered an Independent Director as defined in Nasdaq Listing Rule 5605(a)(2). As a result of Ms. Sainz’s no longer being considered an Independent Director, on October 24, 2022, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications staff (the “Nasdaq Staff”) that the Company is not currently in compliance with the Majority Independent Board requi”
Hyperfine, Inc. reported the full year 2022 results: revenue $7 million to $8 million. Guidance initiated.
“Management expects revenue for the full year 2022 to be $7 million to $8 million.”
Hyperfine, Inc. reported the nine months ended September 30, 2022 results: revenue $5.390 million, net income $60.105 million, EPS net loss of $0.85 per share.
“of $16.392 million, or a net loss of $8.66 per share, for the third quarter of 2021. Nine Months Financial Results • Revenues for the nine months ended September 30, 2022 were $5.390 million, compared to $1.060 million in the nine months ended September 30, 2021. • Gross margin for the nine months ended September 30, 2022 was $0.607 million, compared to $(0.714)”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.